Epalpex 150 SR Tablet contains Epalrestat 150 mg, a potent aldose reductase inhibitor used primarily in the management of diabetic neuropathy. By inhibiting the enzyme aldose reductase, Epalrestat prevents the accumulation of sorbitol in nerve tissues, thereby reducing osmotic and oxidative stress that contribute to nerve damage in diabetic patients. This mechanism helps alleviate symptoms such as numbness, burning sensations, and pain associated with diabetic peripheral neuropathy. Epalpex 150 SR is formulated as a sustained-release tablet to provide a consistent therapeutic effect, improving patient compliance through once-daily dosing. It is indicated for patients with type 2 diabetes who exhibit signs of neuropathic complications, aiming to improve nerve function and quality of life. The medication should be used under medical supervision, with dosage adjustments based on renal and hepatic function. Common side effects may include gastrointestinal discomfort, rash, or elevated liver enzymes, necessitating periodic monitoring during treatment. Epalpex 150 SR Tablet is contraindicated in patients with hypersensitivity to Epalrestat or its components. Overall, Epalpex 150 SR offers an effective option for managing diabetic neuropathy by targeting the underlying biochemical pathways involved in nerve damage.